Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Neuer Top-Geologe an Bord - zündet jetzt die nächste Kursrakete?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14M04 | ISIN: FR0012432516 | Ticker-Symbol: 7PO
Frankfurt
04.06.25 | 08:14
0,699 Euro
-8,27 % -0,063
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
POXEL SA Chart 1 Jahr
5-Tage-Chart
POXEL SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,6400,69904.06.

Aktuelle News zur POXEL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
POXEL Aktie jetzt für 0€ handeln
28.05.POXEL SA: New Clinical and Scientific Data on TWYMEEG to be Presented at the 68th Annual Meeting of the Japan Diabetes Society326Regulatory News: POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology...
► Artikel lesen
26.05.Poxel SA: Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025309PXL065 demonstrated significant benefits in a HCM mouse model preventing pathological myocardial remodeling, including hypertrophy and fibrosis in the heart Presentation of detailed results...
► Artikel lesen
13.05.Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update244TWYMEEG consolidated gross sales in Japan for Sumitomo Pharma Fiscal Year 20241 achieved JPY 7.6 billion (EUR 47,2 million)2, in line with Sumitomo Pharma's latest guidance3 Sumitomo Pharma...
► Artikel lesen
16.04.POXEL SA: Poxel Provides Financial Update for the First Quarter 2025 and Announces the Postponement of its 2024 Full-Year Results444Non-adoption of key financial delegations at the Combined General Meeting held on February 11, 2025 resulted in an adverse and uncertain situation regarding the continuation of the Company's...
► Artikel lesen
08.04.POXEL SA: Poxel Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG Package Insert to Include Type 2 Diabetes Patients with Renal Impairment565Approval by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan enables TWYMEEG (Imeglimin) to be prescribed to type-2 diabetic patients with moderate to severe renal impairment. This...
► Artikel lesen
31.03.Poxel SA: Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment361Newly granted patent covers Imeglimin's use in type-2 diabetic patients with renal impairment and has a patent term in Japan until 2039 This patent further supports Poxel's strategy to...
► Artikel lesen
20.03.Poxel SA: Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy482Hypertrophic cardiomyopathy (HCM) is the most common human genetic cardiac disorder and can lead to serious complications including heart failure and sudden cardiac death The preclinical...
► Artikel lesen
19.02.POXEL SA: Poxel Reports Revenue for the Full Year 2024 and Provides an Update on its Financial Position and Outlook792Following the non-adoption of key financial delegations at the Combined General Meeting held on February 11, 2025, the Company is facing an uncertain and adverse situation regarding the continuation...
► Artikel lesen
11.02.POXEL SA: Poxel Announces Results of its Combined General Meeting Held on February 11, 2025458Regulatory News: POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology...
► Artikel lesen
31.01.POXEL SA: Poxel's partner Sumitomo Pharma reports TWYMEEG gross sales in Japan for Q4 2024 and FY 2024 sales forecast654TWYMEEG sales continued to increase in Japan for the last quarter 2024 (October-December) by 17% over the prior quarter and by 154% over Q4 2023 TWYMEEG's FY 20241 revised forecast2 of...
► Artikel lesen
23.01.Poxel SA: Poxel Announces its Financial Calendar for 2025419Regulatory News: POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology...
► Artikel lesen
21.01.Poxel: Ordinary and Extraordinary General Meeting to Be Held on February 11, 2025413Poxel announces that a Combined General Meeting will be held on February 11, 2025, at 9:00 a.m. CET and the availability of the preparatory documents Poxel announces the addition of a new...
► Artikel lesen
20.01.Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment409Patent life covering Imeglimin in China extended to 2039 Ongoing partnership discussions to develop and market Imeglimin in China, the world's second largest type 2 diabetes market Regulatory...
► Artikel lesen
20.01.POXEL SA: Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG Achieving JPY 5 billion Net Sales in Japan710Poxel eligible for royalties equaling 10% of all TWYMEEG net sales for 20241 and a one-time sales-based payment of JPY 500 million (EUR 3.1 million2 Allocation of all revenues received...
► Artikel lesen
23.12.24Poxel SA: Availability of Poxel's 2024 Half-Year Financial Report745Regulatory News: POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology...
► Artikel lesen
09.12.24POXEL SA: Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook1.054Following the non-adoption of certain financial delegations at the Annual General Meeting of November 28, 2024: Cash runway significantly reduced Redemption of the ORANE held...
► Artikel lesen
29.11.24Poxel SA: Poxel Announces Results from November 28, 2024 Annual General Meeting383Regulatory News: POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology...
► Artikel lesen
07.11.24POXEL SA: Poxel Announces that its Annual General Meeting Will Be Held on November 28, 2024, at 9 am CET and the Availability of Preparatory Documents399Regulatory News: POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology...
► Artikel lesen
06.11.24Poxel Reports Cash and Revenue for the Third Quarter and Nine Months 2024 and Provides Corporate Update573TWYMEEG sales continue to increase in Japan for the last quarter (July-September) by 5% over the prior quarter and by 23% over the 3rd quarter 2023 Poxel expects TWYMEEG net sales in Japan...
► Artikel lesen
04.11.24Dechert LLP: Dechert Advises Poxel on US$50 Million Non-Dilutive Financing Agreement with OrbiMed462PARIS, Nov. 4, 2024 /PRNewswire/ -- Dechert has advised Poxel (Euronext: POXEL), a clinical-stage biopharmaceutical company, on its non-dilutive financing agreement with OrbiMed for US$50...
► Artikel lesen
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1